摘要
目的探讨来氟米特对大鼠抗肾小球基底膜肾炎(Masugi肾炎)的治疗作用及其机制。方法SD大鼠尾静脉注射兔抗大鼠Masugi肾炎抗血清,建立Masugi肾炎模型;用BCA法测量24h尿蛋白变化,光镜、电镜观察肾脏病理改变,免疫荧光法检测IgG变化,并用半定量Western blot的方法观察Wilms瘤抑癌因子(WT-1)蛋白表达水平。结果成功复制大鼠Masugi肾炎模型,来氟米特能减轻Masugi肾炎大鼠蛋白尿、肾脏病变程度,增加病变大鼠足细胞WT-1蛋白水平的表达。结论来氟米特对Masugi肾炎有一定治疗作用,可能机制是通过增加病变大鼠足细胞WT-1蛋白水平表达及减少免疫复合物沉积实现。
Objective To investigate the efficacy and possible machanism of leflunomide in treating anti-GBM nephritis in rats. Methods The rat Masugi nephritis model was induced by injection of rabbit anti-rat glomerular basement membrane serum through tail vein. Twenty-four hours urine protein,WT-1 expression and glomerular lesions were detected by BCA,Western blot,light and electronic microscope,respectively. Results The rat Masugi nephritis model was established successfully. Leflunomide reduced urine protein,glomerular lesions of rat with anti-GBM nephritis,and increased WT-1 expression of nephritic rats. Conclusion Leflunomide plays a role in the treatment of anti-GBM nephritis,possibly by increasing WT-1 expression of nephritic rats and immune complex deposits in the rat model.
出处
《江苏医药》
CAS
CSCD
北大核心
2008年第5期497-499,F0003,共4页
Jiangsu Medical Journal
基金
江苏省自然科学基金(BK2003109)
江苏省医学重点人才工程基金(RC2002045)
